OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


Stage III

In Stage III ovarian cancer, cancer cells have spread to tissues outside the pelvis or to regional lymph nodes. Cancer cells may be found on the outside of the liver.

    • IIIA – Tumor is largely confined to the pelvis but with micro-scopic peritoneal metastases beyond pelvis to abdominal peritoneal surfaces or the omentum.


    • IIIB – Same as IIIA but with macro-scopic peritoneal or omental metastases beyond pelvis less than 2 cm in size


  • IIIC – Same as IIIA but with peritoneal or omental metastases beyond pelvis, larger than 2 cm or lymph node metastases to inguinal, pelvic, or para-aortic areas.

51% of all cases of ovarian cancer are diagnosed when they are Stage III.

Prognosis & Survival Rates
For all types of ovarian cancer taken together, about 3 in 4 women with ovarian cancer live for at least 1 year after diagnosis. Almost half (46%) of women with ovarian cancer are still alive at least 5 years after diagnosis. Women diagnosed when they are younger than 65 do better than older women.

Most women diagnosed with Stage III ovarian cancer have a five-year survival rate of approximately 34%. Survival rates are often based on studies of large numbers of people, but they can’t predict what will happen in any particular person’s case. Other factors impact a woman’s prognosis, including her general health, the grade of the cancer, and how well the cancer responds to treatment.


Relative 5-Year Survival Rate










Treatment for Stage III ovarian cancer is the same as for Stage II ovarian cancer: hysterectomy and bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes), debulking of as much of the tumor as possible, and sampling of lymph nodes and other tissues in the pelvis and abdomen that are suspected of harboring cancer. After surgery, the patient may either receive combination chemotherapy possibly followed by additional surgery to find and remove any remaining cancer.

Your Name (required)

Your Email (required)

Zip Code